VKAs that the effect does not need to be monitored with laboratory tests, at least not in the majority of patients. However, as the drugs are at least in part, eliminated by the kidneys usage in patients with renal insufficiency might need monitoring. Thus, it would be valuable to have access to a test that can indicate if rivaroxaban (and other anticoagulants) has accumulated in the circulation. Intended or unintended overdosing is another possible indication for testing. Furthermore, in bleeding patients on rivaroxaban treatment, it would be helpful to know if the drug is present or not in cases where it may be considered to try to use reversal agents, although there
are not yet any established antidotes. There are some reports on the pharmacokinetic and pharmacodynamic profiles of rivaroxaban, including the general effects on a few coagulation assays (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . However, a more thorough knowledge of how rivaroxaban, at therapeutic and supratherapeutic doses, will affect commonly used coagulation assays is currently lacking. In this study, we have investigated the anticoagulant activity of the direct Xa inhibitor rivaroxaban using different reagents for coagulation assays that are common in clinical laboratories.
Material and Methods

Materials
Rivaroxaban was provided from the manufacturer Bayer Schering Pharma AG, Dimethyl sulfoxide (DMSO) was from Merck (Darmstadt, Germany). Lyophilized normal plasma (Unicalibrator) was purchased from Stago (Asnières sur Seine, France). Evacuated blood collection tube system was from BD (Franklin Lakes, NJ, USA).
Plasma samples
Human blood from 10 adult healthy volunteers, both men and women, was collected in evacuated plastic tubes containing 1:10 volume of 0.129 mol/L tri-sodium citrate as anticoagulant. Ten tubes, in total 50 mL citrated blood, were obtained from each individual. The tubes were centrifuged at 2000 x g for 20 min and the platelet poor plasma was pooled and stored frozen at -70˚C. The plasma was thawed in 37 ˚C waterbath for 15 min and divided into 20 aliquots of 1.0 mL each and "spiked" with rivaroxaban to final concentrations ranging from 0.0 to 1000 µg/L and then stored at -70˚C until analysis. The rivaroxaban was dissolved with 100 % DMSO and all dilutions in plasma was 1:100, resulting in a final DMSO concentration of 1 % (v/v) in all samples, irrespective of the rivaroxaban concentrations.
Coagulation assays
For this investigation we have mainly chosen assays and reagents used in laboratories that are taking part in the external quality programme of laboratory medicine in Sweden (EQUALIS).
The activated partial thromboplastin time (APTT) was assayed using 5 different 
Statistics
Results are presented as mean ± standard deviation (SD). Concentrations required to double the PT or APTT (CT 2 ) were calculated using Excel 97 software (Microsoft®). For PT assays the CT 2 values were calculated by linear regression analysis and for the APTT assays a 2 nd order polynomial function was chosen.
Results
Five different APTT-reagents were used in the study and despite differences in their composition of activating substances and phospholipids, their response to the drug were quite similar. The dose-responses were non-linear ( Table 2 ).
The antithrombin activity assay based on factor Xa-inhibition increased with the rivaroxaban concentration whereas the other assays, based on thrombin inhibition,
were not affected (Fig. 3) . Linear regression analysis gave in a slope that corresponded to an increase of 0.09 IU/mL per 100 µg/L rivaroxaban.
The fibrinogen content, determined with four different Clauss type fibrinogen assays, were almost unaffected by rivaroxaban in plasma (not shown). The differences between no drug (0 µg/L) and the expected peak concentration of 200 µg/L were between 0.02 g/L (Multifibren U) to -0.17 g/L (Fibrinogen-C). At the highest rivaroxaban concentration all assays gave fibrinogen levels that were approx. 10 % lower than the basal level.
The APC resistance assays were also different in their sensitivity towards rivaroxaban ( Fig. 4 A and B) . 
Discussion
Rivaroxaban is an oral, direct FXa inhibitor that not only has the capacity to inactivate free FXa but also clot-associated FXa activity and the FXa that is part of the prothrombinase complex (3). Thus, rivaroxaban has the potential to down-regulate the coagulation processes very efficiently and therefore may also interfere in many coagulation assays in which FXa activity has an impact on the results obtained with the assay system. This has also been shown for some global clotting tests such as the Quick PT, APTT and the prothrombinase-induced clotting time (PiCT) assays (3-7, 9, 10) and for more specialized assays such as FXa activity and endogenous thrombin potential (5, 6, 14) .
In this investigation we have focused on commonly used coagulation assays and included several different reagents in order to get a picture of the differences in sensitivities within each assay group. An in vitro approach was chosen because of its relative simplicity and the fact that rivaroxaban is not a prodrug and display high specificity and predictable pharmacokinetic properties that make it possible to mimic a real life situation. The selected plasma concentration interval was based on the expected concentrations obtained from published dose-ranging studies where oncedaily or twice-daily dosing of different amounts of rivaroxaban have been described Tables 1 and 2 . In our study, we included up to 4-5-fold higher concentrations (1000 µg/L) than the expected peak level, which may be found if the drug has accumulated in the circulation for some reason (e.g., kidney failure) or if too much of the drug has been ingested.
We observed that the APTT is more sensitive to rivaroxaban than the Owren type PT assays. This is in contrast to earlier findings based on the Quick PT assays (3-6) that concluded that the PT is in general more sensitive than the APTT. In the paper by values for the PT assays were higher (Table 2) , especially for the Owren type PT assays. However, in a later study by Mueck et al. it was shown that different Quick PT reagents differ considerably in rivaroxaban sensitivity (10) . In their study they showed that the correlation between rivaroxaban concentration in plasma and PT followed a simple linear intercept model but one PT reagent gave a slope of 0.8 seconds/(100 µg/L) and the other a slope of 3.2 seconds /(100 µg/L). In our study, the corresponding slopes varied between 1.5 to 3.6 seconds/(100 µg/L), which further illustrates the variability between reagents. With this observation one should be cautious to suggest that the conventional PT assay can be an appropriate coagulation test to assess the plasma concentration of rivaroxaban (10) . A recent study by Samama, with the aim to measure the rivaroxaban pharmacodynamics,
showed that the PT reagent variations could not be reduced by INR calibration (16) .
However, as the PT assay response was linear over a broad concentration range it was suggested that the effect of rivaroxaban could be expressed as plasma concentration of rivaroxaban if plasma probes with rivaroxaban were used to calibrate the assay (16) . In this study we also showed that the Owren PT assay is, in general, less sensitive to rivaroxaban compared to the Quick PT type, which is also illustrated by the high CT 2 values (table 2) for the four Owren type PT reagents used in this study. The reason for the observed differences is probably partly explained by the higher final dilution of the plasma sample, 1:21 in Owren PT compared to 1:3 in Quick PT, which makes the Owren PT type less sensitive for interfering substances as has been shown previously for other anticoagulant drugs (17) . However, other less obvious factors may also be of importance as there are PT reagents of both Quick and Owren type with intermediate sensitivities.
The 5 different APTT reagents that were investigated in this study represented a variety of commonly used activators and phospholipids but nevertheless the dose response to rivaroxaban was quite similar. The calculated CT 2 values differed only 1.6 fold between the two reagents with the highest and lowest values, respectively (Table 1 ). In fact, the inter-individual differences between the 10 plasma samples at peak concentrations using the same reagent could differ to the same extent. At trough level (25 µg/L), only few samples had prolonged APTT. Interestingly, the most prolonged APTT at this low concentration for all five different reagents was from the same donor, indicating that the inter-individual differences observed may be explained by properties of the sample rather than the reagent. For the clinician, it is important to note that rivaroxaban may be the only explanation for a prolonged APTT if the sample is drawn a few hours after ingestion of the drug. If a repeat test just before the next rivaroxaban dose shows a considerable shortening of the APTT no further testing is needed, at least not in the non-bleeding patient.
The results from the antithrombin testing (Fig.3) were not surprising and clearly illustrated that this assay is dependent on the type of enzyme used in the reagent.
While the reagents based on bovine or human thrombin were left unaffected, the amidolytic activity of the factor Xa-based assay was inhibited in a dose-dependent manner by rivaroxaban. A crude estimate by linear regression analysis indicated that the antithrombin activity was increased by 0.09 IU/mL per 100 µg/L rivaroxaban in plasma. This means, that an inherited antithrombin deficiency associated with thromboembolic disease, with antithrombin levels around 0.60 IU/mL, could be missed if a thrombophilia investigation is performed during rivaroxaban therapy.
Not unexpectedly, the fibrinogen assays tested were only affected to a minor extent.
As the Clauss type of fibrinogen assays are based on thrombin as a fibrinogen to fibrin converting enzyme it was not anticipated that the Xa-inhibitor would affect this type of assay principle. However, the observed changes were all indicating a small dose dependency and at the maximum rivaroxaban concentration (1000 µg/L) all four reagents gave approx. 10 % lower values compared to the basal fibrinogen levels (not shown). The changes within the expected therapeutic concentration range were considered clinically insignificant but the reason for the lowered fibrinogen with increasing rivaroxaban is unclear.
The two types of assays for the determination of APC resistance were also differently affected by rivaroxaban. The APTT-based assay was moderately affected by rivaroxaban with an apparent linear increase of the APC resistance ratio (Fig. 4a .
One of the donors expressed an APC-resistant phenotype with a ratio of 1.7 that is probably explained by heterozygosity for the factor V Leiden mutation. At an expected peak concentration of rivaroxaban (200 µg/L) this ratio had only increased by 0.1 to 1.8 and would probably not be misclassified as a normal phenotype.
Nevertheless, with the knowledge that there may be a considerable inter-individual variation regarding the underlying APTT determination the risk of misclassification with this type of test must be further investigated using donors with known APC resistance genotype. The other type of APC resistance assay was not influenced to the same extent (Fig. 4b) , probably explained by the different mode of activation that eliminates the influence of factor Xa. Despite this, there was a dose dependent prolongation of the underlying coagulation times. At very high concentrations the ratios were markedly increased in the samples from some donors. The reason for this effect is unknown and warrants further investigations before the assay can be recommended to be used during rivaroxaban therapy.
As rivaroxaban has several advantages compared to warfarin it is likely to believe that it will be used as an anticoagulant in a considerable number of patients in a near future (if approved for the same indications). The drug affects global coagulation assays such as the APTT and PT and will probably affect most tests that rely on the activity of factor Xa. However, considerable differences between reagents within the same assay group, combined with an inter-individual variability to the drug, will make it difficult to create general information on the rivaroxaban effects on common laboratory assays. Our investigations indicate that at concentrations close to the expected peak concentration the APTT will be prolonged but the effect on the PT assays is weak. Thus, the APTT and PT are not useful to measure the plasma concentration of rivaroxaban and can merely be used to obtain a crude estimate. If the aim is to measure the pharmacodynamic effect of rivaroxaban more specific assays, preferably based on factor Xa-inhibition, should be used. Another conclusion is that a useful laboratory screening for thrombophilia cannot not be performed during rivaroxaban therapy without knowledge about how the drug affects the locally used assays. The results obtained in our study will facilitate for laboratories to adequately handle the effect of the drug on common coagulation assays. 
